Exero Medical
Exero Medical Announces Smart Sensor Granted FDA Breakthrough Designation
To confirm that Exero’s smart sensor may provide effective early diagnosis of AL, the FDA scrutinized the company’s pre-clinical data from its animal studies as well as clinical data collected in the first-in-human feasibility trial conducted at Rabin Medical Center.
Exero Medical Completes First In-Human Implant of Wireless Anastomotic Leak Sensor at Rabin Medical Center
Dr. Erez Shor, CEO of Exero Medical stated: “We are extremely encouraged by this successful first case and the technical performance of the device in the operating room. This is a significant milestone for Exero Medical.
Rabin Medical Center Announced They Will Initiate Clinical Trials to Test Feasibility of Exero Medical’s Wireless Anastomotic Sensor
Researchers at Rabin Medical Center will use Exero’s system to collect data from the sensor during low anterior resection surgery. The results of the trial will enable the company to refine its detection algorithms based on real-life data.
